Commentary on “Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial” by Gautret et al by Mondher Toumi, Samuel Aballea

Get full text

An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. by Ayman Chit, Julie Roiz, Samuel Aballea

Get full text

Measuring health-related quality of life in young children: how far have we come? by Nicola Germain, Samuel Aballéa, Mondher Toumi

Get full text

Use of Patient Preference Information in Benefit–Risk Assessment, Health Technology Assessment, and Pricing and Reimbursement Decisions: A Systematic Literature Review of Attempts... by Lylia Chachoua, Monique Dabbous, Clément François, Clément François, Claude Dussart, Samuel Aballéa, Samuel Aballéa, Mondher Toumi, Mondher Toumi

Get full text

On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in Europe by Katarzyna Jabłońska, Samuel Aballéa, Pascal Auquier, Mondher Toumi

Get full text

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results by Junwen Zhou, Aurélie Millier, Clément François, Samuel Aballéa, Mondher Toumi

Get full text

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach by Ru Han, Shuyao Liang, Clément François, Samuel Aballea, Emilie Clay, Mondher Toumi

Get full text

Cost-effectiveness of fluocinolone acetonide implant (ILUVIEN®) in UK patients with chronic diabetic macular oedema considered insufficiently responsive to available therapies by Michal Pochopien, Annette Beiderbeck, Phil McEwan, Richard Zur, Mondher Toumi, Samuel Aballéa

Get full text

Determinants of orphan drugs prices in France: a regression analysis by Daria Korchagina, Aurelie Millier, Anne-Lise Vataire, Samuel Aballea, Bruno Falissard, Mondher Toumi

Get full text

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK by Zalmai Hakimi, Con Kelleher, Samuel Aballéa, Khaled Maman, Jameel Nazir, Colette Mankowski, Isaac Odeyemi

Get full text

Analysis of health economics assessment reports for pharmaceuticals in France – understanding the underlying philosophy of CEESP assessment by Mondher Toumi, Anastasiia Motrunich, Aurélie Millier, Cécile Rémuzat, Christos Chouaid, Bruno Falissard, Samuel Aballéa

Get full text

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models by Michał Pochopień, Ewelina Paterak, Emilie Clay, Justyna Janik, Samuel Aballea, Małgorzata Biernikiewicz, Mondher Toumi

Get full text

Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysisResearch in context by Damien Etchecopar-Etchart, Dong Keon Yon, Piotr Wojciechowski, Samuel Aballea, Mondher Toumi, Laurent Boyer, Guillaume Fond

Get full text

Risk factors for cervical cancer in women in China: A meta-model by Samuel Aballéa, Ekkehard Beck, Xiao Cheng, Nadia Demarteau, Xiao Li, Fangfang Ma, Mohamed Neine, Fang-Hui Zhao

Get full text

Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment by Natalia Hawken, Saku Torvinen, Mohamed-Elmoctar Neine, Ikbel Amri, Mondher Toumi, Samuel Aballéa, Adam Plich, Nicolas Roche

Get full text

Health economic evaluation of gene replacement therapies: methodological issues and recommendations by Samuel Aballéa, Katia Thokagevistk, Rimma Velikanova, Steven Simoens, Lieven Annemans, Fernando Antonanzas, Pascal Auquier, Clément François, Frank-Ulrich Fricke, Daniel Malone, Aurélie Millier, Ulf Persson, Stavros Petrou, Omar Dabbous, Maarten Postma, Mondher Toumi

Get full text